SMILES: Study of Montelukast in Sickle Cell Disease

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 16, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Anemia, Sickle CellSleep-Disordered Breathing
Interventions
DRUG

Montelukast

Montelukast is used to treat and prevent asthma. It will decrease the symptoms and the number of acute asthma attacks. However this medicine should not be used to relieve an asthma attack that has already started.

OTHER

Oral Placebo

Inert chewable tablet with no therapeutic value

Trial Locations (1)

WC1N 1EH

RECRUITING

Great Ormond Street Hospital NHS Foundation Trust, London

All Listed Sponsors
collaborator

Guy's and St Thomas' NHS Foundation Trust

OTHER

collaborator

University College London Hospitals

OTHER

collaborator

North Middlesex University Hospital

OTHER

collaborator

King's College Hospital NHS Trust

OTHER

collaborator

The Whittington Hospital NHS Trust

OTHER_GOV

lead

Great Ormond Street Hospital for Children NHS Foundation Trust

OTHER